The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Hereditary breast cancer
Open accessAbstract
Hasta el 10 % de los pacientes con cáncer de mama (CM) han heredado mutaciones en línea germinal que a menudo conducen a la pérdida de la función de los genes implicados en la reparación del ADN y a la activación del punto de control del ciclo celular.Además de los genes BRCA1 y BRCA2, se ha establecido asociación con riesgo elevado o moderado de cáncer de mama para otros genes, como PALB2, ATM y CHEK2.La incorporación de técnicas de NGS al estudio genético permite su identificación.Los individuos portadores sanos y afectados pueden beneficiarse de recomendaciones de medidas de detección precoz y de reducción de riesgo.Actualmente, las opciones de tratamiento son limitadas para los pacientes con CM mutado en gBRCA.Los inhibidores de la poli(ADP-ribosa) polimerasa (PARP) son una opción terapéutica dirigida que ha demostrado actividad en el cáncer de mama hereditario.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
Dbouk, M., Katona, B. W., Brand, R. E., Chak, A., Syngal, S., Farrell, J. J., Kastrinos, F., Stoffel, E. M., Blackford, A. L., Rustgi, A. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00298 · Cited by 247
Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.008 · Cited by 32
Cited by
Dhivya, S., Padma, V. V., & Santhini, E. (2015) · BioMedicine · doi:10.7603/s40681-015-0022-9 · Cited by 1,526
Kuhl, C. K., Schrading, S., Leutner, C. C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,147
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Liu, H., Wang, C., Li, C., Qin, Y., Wang, Z., Yang, F., Li, Z., & Wang, J. (2018) · RSC Advances · doi:10.1039/c7ra13510f · Cited by 915
Wound dressings: Current advances and future directions
Rezvani Ghomi, E., Khalili, S., Nouri Khorasani, S., Esmaeely Neisiany, R., & Ramakrishna, S. (2019) · Journal of Applied Polymer Science · doi:10.1002/app.47738 · Cited by 878
Metadata
- Authors
- Andrés Conejero, R., Lastra del Prado, R., Zurera Berjaga, M., & Arévalo Vázquez, E.
- Venue
- Revisiones en Cáncer
- Publisher
- ARAN Ediciones
- Published
- 2022
- ISSN
- 0213-8573 (ISSN-L)
- OpenAlex
- W4317422726
- Cited by
- 193
- References
- 6
- FWCI
- 0.00
- Type
- journal article
- Language
- es
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hereditary breast cancer. https://app.cochat.ai/papers/10.20960/revcancer.00003
- The paper
- Andrés Conejero, R., Lastra del Prado, R., Zurera Berjaga, M., & Arévalo Vázquez, E. (2022). Hereditary breast cancer. Revisiones en Cáncer. https://doi.org/10.20960/revcancer.00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.